Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03061890 · ClinicalTrials.gov registry record
Developmental Impact of NICU Exposures (DINE)
A clinical trial, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- 600
- Enrollment target
NCT03061890: Completed study, sponsored by Albert Einstein College of Medicine.
NCT03061890 is a clinical trial that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 600 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03061890 has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
Study Summary
The DINE study will test the hypothesis that potentially avoidable NICU-based exposures contribute to the neuro-cognitive and somatic impairments prevalent among NICU graduates. This hypothesis is drawn from the documented impact of phthalate exposure on early development in term-born children, and the acknowledged presence of these toxic chemicals in the NICU. Third trimester in utero exposure to phthalates have been linked to poorer childhood performance in cognition, motor function, attention, hyperactivity and social behavior. Phthalate exposure is also associated with altered onset of puberty and asthma. The multi-site cohort and approach will clarify the role of NICU-based phthalate exposure on high-prevalence clinical outcomes.
Primary Outcome
Brief Respiratory Questionnaire to determine association between exposure and lung health
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2017-04-01 |
| Est. Completion | 2023-08-31 |
What the finished NCT03061890 record still lists
NCT03061890 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03061890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03061890 about?
NCT03061890 is a clinical study titled "Developmental Impact of NICU Exposures (DINE)". The DINE study will test the hypothesis that potentially avoidable NICU-based exposures contribute to the neuro-cognitive and somatic impairments prevalent among NICU graduates. This hypothesis is drawn from the documented impact of phthalate exposure on early development in term-born children, and ...
What is the current status of trial NCT03061890?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2017-04-01. Estimated completion is 2023-08-31.
Who is sponsoring clinical trial NCT03061890?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI